SCHEMBL2197329

SCHEMBL2197329

CC(C)(C)OC(=O)N1CCN(C(=O)c2ccc(F)c(O)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
MGLL Q99685 3/20 0.51
FAAH O00519 2/20 0.50
HDAC4 P56524 1/20 0.50
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
CNR2 P34972 1/20 0.48
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
CRBN Q96SW2 1/20 0.47
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
SERPINE1 P05121 1/20 0.46
EPHX2 P34913 2/20 0.46
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.45
GPR119 Q8TDV5 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623942 0.84 KMT2A (0.57) MEN1KMT2AHDAC4CNR2CRBN
SCHEMBL1512449 0.83 MEN1 (0.56) MEN1KMT2AHDAC4PDK1PDK2
SCHEMBL2365945 0.83 MEN1 (0.56) MEN1KMT2AMGLLHDAC4PDK1
SCHEMBL12217609 0.83 KMT2A (0.59) MEN1KMT2AHDAC4PDK1PDK2
SCHEMBL20502533 0.83 MEN1 (0.56) MEN1KMT2AHDAC4PDK1PDK2
SCHEMBL3093877 0.82 MEN1 (0.68) MEN1KMT2AHDAC4HSP90AA1ABL1
SCHEMBL14992693 0.82 MAPT (0.56) MEN1KMT2APDK2LMNAGPR119
SCHEMBL28677764 0.81 MEN1 (0.54) MEN1KMT2AHDAC4PDK1PDK2
SCHEMBL5537347 0.80 KMT2A (0.70) MEN1KMT2AHDAC4PDK1PDK2
SCHEMBL34473978 0.80 MEN1 (0.53) MEN1KMT2AHDAC4PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-07-14 US disclosed
EP-2065369-A1 UREA COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF FAAH, FAAH2, UTS2R MEN1 4707/4885KMT2A 1156/4885MGLL 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.